Mr. Andre Larente reports

DIAGNOS ANNOUNCES CLOSING OF SECOND AND FINAL TRANCHE OF PRIVATE PLACEMENT

Diagnos Inc. has closed a second and final tranche of 3,502,931 units issued at a price of 28 cents per unit, for gross proceeds of $980,820.68, of a non-brokered private placement initially announced on May 9, 2024. Combined with the first closing announced on May 9, 2024, the aggregate number of units is 4,627,931, and the aggregate gross proceeds amount to $1,295,820.68.

Each unit consists of:

• One common share;
• One common share warrant.

As part of the closing of the second and final tranche of the private placement, 3,502,931 warrants have been issued to the subscribers. Each warrant can be exercised to purchase one share at a price of 40 cents per share for a period of 18 months ending Dec. 5, 2025. Combined with the first closing announced on May 9, 2024, the aggregate number of warrants issued as part of the private placement is 4,627,931.

The net proceeds from the private placement will be used to finance product development and commercialization of artificial-intelligence-based screening services, as well as general and administrative operations.

In connection with the closing of the second and final tranche of the private placement, the corporation: (i) paid cash commissions amounting to $27,804.01 to three qualified firms acting at arm's length; and (ii) issued an aggregate number of 86,800 finders' warrants to two qualified firms acting at arm's length. Each finder's warrant entitles the holder to purchase one share at an exercise price of 40 cents per share for a period of 18 months ending Dec. 5, 2025.

All securities issued as part of the second and final tranche of the private placement are subject to a statutory hold period ending Oct. 6, 2024. The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.